ResMed Inc. filings document operating results, governance actions, capital returns and securities registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and fiscal-year financial results, record board-declared cash dividends and describe the treatment of NYSE common stock and ASX CHESS Depositary Interests in dividend payments.
The company’s regulatory record also covers board composition, director elections, executive officer transitions, compensation arrangements and amendments to the ResMed Inc. 2009 Incentive Award Plan. Proxy materials provide stockholder voting matters, executive compensation disclosure and corporate-governance information for the medical technology company’s public-company structure.
Michael J. Farrell, Chief Executive Officer of ResMed Inc. (RMD), reported transactions on Form 4 relating to common stock and stock options. On 09/08/2025 he acquired 8,009 shares at $101.64 per share under a Rule 10b5-1 plan adopted October 31, 2024, and sold 8,009 shares in multiple trades at a weighted-average price of $278.1359 (trade prices ranged $275.27–$279.57). Following the reported transactions his direct beneficial ownership is reported as 475,801 shares after the purchase and 467,792 shares after the sale, with an additional 2,090 shares held indirectly via the Lisette and Michael Farrell Family Trust. He also reports holding 16,020 options exercisable through 11/14/2025; options vest one-third per year.
ResMed Inc. (RMD) Form 144 reports a proposed sale of 8,009 common shares through Fidelity Brokerage Services with an aggregate market value of $2,227,590.84. The filing lists approximately 146,414,839 shares outstanding and an intended sale date of 09/08/2025 on the NYSE.
The shares were acquired under an option granted on 11/14/2018 and shown as acquired on 09/08/2025, with payment in cash. The filer previously sold 8,009 shares on 06/09/2025, 07/07/2025 and 08/07/2025 with gross proceeds of $2,011,909.65, $2,056,076.09 and $2,238,378.55, respectively.
ResMed Inc. (RMD) Form 4: Director Nicole Mowad-Nassar was granted 241 restricted stock units (RSUs) on 09/02/2025. The report shows the award as a non-derivative acquisition and lists 241 shares beneficially owned following the transaction, held in a direct form. The filing explains the RSUs vest on the first anniversary of the grant date. The Form 4 was signed on behalf of Ms. Mowad-Nassar by an attorney-in-fact on 09/03/2025. No price was reported for the grant and no other transactions or derivative positions are disclosed in this filing.
ResMed insider trades on 09/02/2025: Chief Financial Officer Brett Sandercock executed both an acquisition and a sale in ResMed common stock under a Rule 10b5-1 plan. He acquired 2,000 shares at $101.64 per share and sold 3,000 shares at $270.77 per share. Following these transactions his beneficial ownership is reported as 87,745 shares. The 2,000-share purchase reflects option-related activity: a grant of 2,000 options with an exercise price of $101.64 exercisable beginning 11/11/2019 and expiring 11/14/2025; options vest one-third per year. The Form 4 indicates the trades were made pursuant to a 10b5-1 trading plan adopted February 19, 2025.
ResMed Inc. director reports no beneficial ownership
ResMed Inc. director Nicole Mowad-Nassar filed an initial Form 3 ownership report in connection with an event dated 08/15/2025. The filing states that she serves as a Director of ResMed Inc. and that no securities are beneficially owned, with both the non-derivative and derivative ownership tables showing no holdings.
ResMed insider notice to sell 3,000 common shares via Fidelity on 09/02/2025. The filing reports an aggregate market value of $812,310 for the proposed sale and states the company has 146,414,839 shares outstanding. The shares to be sold were acquired through an options grant (11/14/2018) covering 2,000 shares and restricted stock vesting on 11/11/2022 (204 shares) and 11/18/2022 (796 shares). The filer also disclosed three prior sales over the past three months by Brett Sandercock totaling 7,883 shares for gross proceeds of $2,087,372.17. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.
Justin Leong, Chief Product Officer of ResMed Inc. (RMD), reported that 5,462 shares of company stock were acquired on 08/15/2025 upon the vesting of performance-based restricted stock units. These units were originally granted on 11/20/2024 and were certified as earned by the compensation committee when the performance metrics were met.
Following the transaction, Mr. Leong beneficially owns 27,180 shares. The reported acquisition shows a transaction code of A(1) with a reported price of $0, consistent with earned compensation rather than a market purchase.
Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), reported that 5,462 shares of ResMed common stock were issued to him on 08/15/2025 as the result of performance-based restricted stock units (RSUs) granted on 11/20/2024. The filing shows the shares were earned when the company's compensation committee certified that the performance metrics were met; the RSUs have a vesting schedule of one-third each anniversary of the grant.
Following this issuance, Mr. Sandercock beneficially owns 88,745 shares. The reported transaction lists a price of $0, reflecting the settlement of vested RSUs rather than an open-market purchase, and the Form 4 is signed and dated 08/19/2025.
ResMed Inc. Chief Executive Officer Michael J. Farrell reported the vesting and receipt of performance-based restricted stock units. On 08/15/2025, 12,289 shares of ResMed common stock were acquired at a $0 price because they were earned under a performance-based restricted stock unit award granted 11/20/2024 after the compensation committee certified that performance metrics were met. After the transaction, Farrell beneficially owned 467,792 shares directly and held an indirect interest in 2,090 shares through the Lisette and Michael Farrell Family Trust. The award vests one-third each year on the grant anniversary.
ResMed Inc director John Hernandez exercised options for 2,575 shares of ResMed Common Stock at $148.9000 per share on August 18, 2025, then sold 2,575 shares at a weighted average price of $287.1026. Following these transactions, he holds 4,045 common shares directly.